{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T23:17:18Z","timestamp":1783552638850,"version":"3.55.0"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"10","funder":[{"name":"National Institute of Child Health and Human Development","award":["5K12HD085816-08"],"award-info":[{"award-number":["5K12HD085816-08"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study aimed to evaluate the feasibility of randomizing patients to weight-based low molecular weight heparin (LMWH) versus no pharmacologic thromboprophylaxis following cesarean delivery (CD).<\/jats:p>\n                  <jats:p>Single-center, open-label pilot randomized controlled trial of individuals aged 18+ undergoing CD at the University of Utah Health from November 2023 to June 2024. Those with a contraindication to anticoagulation, a plan for therapeutic anticoagulation, or considered at highest risk for postpartum venous thromboembolism (VTE; i.e., undergoing cesarean-hysterectomy, high-risk thrombophilia, personal history of thromboembolism) were excluded. Enrolled individuals were randomized in a 1:1 ratio utilizing block randomization with randomly varying block sizes to receive weight-based LMWH for 14 days or no pharmacologic thromboprophylaxis. The primary outcome was feasibility, defined as \u226535% enrollment of eligible individuals and retention of \u226585% of enrolled individuals through all study procedures. Secondary feasibility outcomes included the number of eligible patients per month, approach rate, enrollment rate, and retention rate. Additional outcomes included VTE, wound hematoma, patient-reported symptoms, or a bleeding complication within 6 weeks postpartum. Baseline characteristics were compared between those approached and enrolled and those not enrolled. The proportion meeting each of the outcomes was reported with 95% confidence intervals (CI).<\/jats:p>\n                  <jats:p>Over the 6-month study period, 694 patients were screened and found eligible for an average of 106 eligible patients per month. There were 611 patients approached (88%, 95% CI: 85.6\u201390.5), of which 64 enrolled (10.5%, 95% CI: 8\u201312.9), and 61 participants were retained through all study procedures (95.3%, 95% CI: 90\u2013100). Thus, the overall primary outcome feasibility parameters were not met. Among the 64 individuals enrolled and randomized, the mean age was 31.0 years (standard deviation: 5.5 years), and the majority were non-Hispanic White (56%). Baseline characteristics were similar between those who were approached and enrolled compared with those not enrolled. There were no differences in additional clinical outcomes (VTE, wound hematoma, patient-reported symptoms, or bleeding complications) by prophylaxis group.<\/jats:p>\n                  <jats:p>In this pilot trial, individual patient randomization to weight-based LMWH or no pharmacologic thromboprophylaxis after CD was not feasible due to low enrollment rates. Future trials addressing postpartum thromboembolism prevention should consider alternative study designs.<\/jats:p>","DOI":"10.1055\/a-2753-9286","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:27:04Z","timestamp":1764116824000},"page":"1328-1334","source":"Crossref","is-referenced-by-count":0,"title":["Low Molecular Weight Heparin Thromboprophylaxis or No Treatment following Cesarean Delivery: A Pilot Randomized Controlled Trial"],"prefix":"10.1055","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct06118957","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ann M.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Allshouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D W.","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torri D.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/AOG.0000000000002062","article-title":"The case for a national maternal mortality review committee","volume":"130","author":"S L Clark","year":"2017","journal-title":"Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"ACOG practice bulletin no. 196. American College of Obstetricians and Gynecologists","volume":"132","author":"Thromboembolism in Pregnancy","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2005.11.008","article-title":"Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality","volume":"194","author":"A H James","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08956.x","article-title":"Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study","volume":"156","author":"A A Sultan","year":"2012","journal-title":"Br J Haematol"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa1311485","article-title":"Risk of a thrombotic event after the 6-week postpartum period","volume":"370","author":"H Kamel","year":"2014","journal-title":"N Engl J Med"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/AOG.0000000000000230","article-title":"Postpartum venous thromboembolism: incidence and risk factors","volume":"123","author":"N K Tepper","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.0007-1323.2001.01800.x","article-title":"Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery","volume":"88","author":"P Mismetti","year":"2001","journal-title":"Br J Surg"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"M K Gould","year":"2012","journal-title":"Chest"},{"key":"ref9","volume-title":"Thrombosis and embolism during pregnancy and thepuerperium, reducing the risk","author":"Royal College of Obstetrician and Gynaecologists","year":"2015"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.ajog.2020.04.032","article-title":"Society for Maternal-Fetal Medicine Consult Series #51: thromboembolism prophylaxis for cesarean delivery","volume":"223","author":"L D Pacheco","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/AOG.0000000000001579","article-title":"National partnership for maternal safety: consensus bundle on venous thromboembolism","volume":"128","author":"M E D\u02bcAlton","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref12","first-page":"CD001689","article-title":"Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period","volume":"3","author":"P Middleton","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/AOG.0000000000005122","article-title":"Efficacy of postpartum pharmacologic thromboprophylaxis: a systematic review and meta-analysis","volume":"141","author":"M C Oakes","year":"2023","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"128.e1","DOI":"10.1016\/j.ajog.2023.11.013","article-title":"Postpartum pharmacologic thromboprophylaxis and complications in a US cohort","volume":"231","author":"A M Bruno","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/AOG.0000000000004521","article-title":"Evaluation of a risk-stratified, heparin-based, obstetric thromboprophylaxis protocol","volume":"138","author":"M Y Lu","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/AOG.0000000000004554","article-title":"Postpartum heparin thromboprophylaxis: more harm than good","volume":"138","author":"A Kotaska","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"08","key":"ref17","first-page":"835","article-title":"A randomised double-blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study","volume":"108","author":"R F Burrows","year":"2001","journal-title":"BJOG"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ajog.2004.03.039","article-title":"Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin","volume":"191","author":"S Gates","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1160\/TH14-06-0485","article-title":"Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial","volume":"113","author":"M A Rodger","year":"2015","journal-title":"Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2016.04.004","article-title":"Low molecular weight heparin to prevent postpartum venous thromboembolism: a pilot study to assess the feasibility of a randomized, open-label trial","volume":"142","author":"M A Rodger","year":"2016","journal-title":"Thromb Res"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/AOG.0000000000004937","article-title":"Weight-based compared with fixed-dose enoxaparin prophylaxis after cesarean delivery: a randomized controlled trial","volume":"140","author":"A M Bruno","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/AOG.0000000000000873","article-title":"Enoxaparin dosing after cesarean delivery in morbidly obese women","volume":"125","author":"R T Overcash","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.ajogmf.2023.100988","article-title":"Comparison of postpartum anti-Xa levels following enoxaparin administration to prevent venous thromboembolism using 2 weight-based protocols: a randomized controlled trial","volume":"5","author":"R Haj","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/jp.2015.130","article-title":"A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women","volume":"36","author":"M L Stephenson","year":"2016","journal-title":"J Perinatol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1213\/ANE.0000000000002530","article-title":"The Society for Obstetric Anesthesia and Perinatology Consensus Statement on the anesthetic management of pregnant and postpartum women receiving thromboprophylaxis or higher dose anticoagulants","volume":"126","author":"L Leffert","year":"2018","journal-title":"Anesth Analg"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-10-1","article-title":"A tutorial on pilot studies: the what, why and how","volume":"10","author":"L Thabane","year":"2010","journal-title":"BMC Med Res Methodol"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j..2002.384.doc.x","article-title":"Design and analysis of pilot studies: recommendations for good practice","volume":"10","author":"G A Lancaster","year":"2004","journal-title":"J Eval Clin Pract"},{"issue":"15","key":"ref28","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2015.10962","article-title":"Pilot studies: a critical but potentially misused component of interventional research","volume":"314","author":"C Kistin","year":"2015","journal-title":"JAMA"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e3181d9d421","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"115","author":"K F Schulz","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1016\/j.jtha.2024.06.019","article-title":"Preferences of pregnant women for postpartum thromboprophylaxis: the bicentric prefer-postpartum study","volume":"22","author":"M Blondon","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/1471-0528.17943","article-title":"Preventing postpartum venous thromboembolism with low-molecular-weight heparin: the PP-HEP pilot randomised controlled trial","volume":"132","author":"M Blondon","year":"2024","journal-title":"BJOG"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/AOG.0000000000001656","article-title":"Pharmacologic thromboprophylaxis in obstetrics: broader use demands better data","volume":"128","author":"B M Sibai","year":"2016","journal-title":"Obstet Gynecol"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2753-9286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:47:55Z","timestamp":1783550875000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2753-9286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2753-9286","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,25]]},"published":{"date-parts":[[2025,11,25]]}}}